ASCO - American Society of Clinical Oncology

01/24/2022 | Press release | Distributed by Public on 01/24/2022 16:09

Ripretinib Demonstrates Comparable Efficacy and Fewer Side Effects Compared to Sunitinib in Patients with GIST Previously Treated With Imatinib